Unknown

Dataset Information

0

Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital.

ABSTRACT: Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were treated with pirfenidone at doses

SUBMITTER: Song MJ 

PROVIDER: S-EPMC7719184 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital.

Song Myung Jin MJ   Moon Sung Woo SW   Choi Ji Soo JS   Choi Ji Soo JS   Lee Sang Hoon SH   Lee Su Hwan SH   Chung Kyung Soo KS   Jung Ji Ye JY   Kang Young Ae YA   Park Moo Suk MS   Kim Young Sam YS   Chang Joon J   Kim Song Yee SY  

Scientific reports 20201204 1

Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were treated with pirfenidone at doses < 1200 mg/day (low-dose grou  ...[more]

Similar Datasets

Unknown Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
| S-EPMC7029533 | biostudies-literature
Unknown Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
| S-EPMC8699661 | biostudies-literature
Unknown Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).
| S-EPMC7700641 | biostudies-literature
Unknown A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
| S-EPMC7569556 | biostudies-literature
Unknown Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
| S-EPMC6967051 | biostudies-literature
Unknown Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
| S-EPMC6156214 | biostudies-literature
Unknown Comparison of Prevailing Insulin Regimens at Different Time Periods in Hospitalized Patients: A Real-World Experience from a Tertiary Hospital.
| S-EPMC9171166 | biostudies-literature
Unknown Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
| S-EPMC7580189 | biostudies-literature
Unknown Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
| S-EPMC8795224 | biostudies-literature
Unknown Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
| S-EPMC6092682 | biostudies-literature